GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Cyclically Adjusted Revenue per Share

Meridian Bioscience (Meridian Bioscience) Cyclically Adjusted Revenue per Share : $6.26 (As of Sep. 2022)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Meridian Bioscience's adjusted revenue per share for the three months ended in Sep. 2022 was $1.466. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.26 for the trailing ten years ended in Sep. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-23), Meridian Bioscience's current stock price is $33.97. Meridian Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $6.26. Meridian Bioscience's Cyclically Adjusted PS Ratio of today is 5.43.


Meridian Bioscience Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Meridian Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Cyclically Adjusted Revenue per Share Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.66 4.78 5.02 5.56 6.26

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.56 5.74 6.03 6.23 6.26

Competitive Comparison of Meridian Bioscience's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Meridian Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meridian Bioscience's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Cyclically Adjusted PS Ratio falls into.



Meridian Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Meridian Bioscience's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=1.466/125.2265*125.2265
=1.466

Current CPI (Sep. 2022) = 125.2265.

Meridian Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 1.086 96.871 1.404
201303 1.127 98.209 1.437
201306 1.122 98.518 1.426
201309 1.166 98.790 1.478
201312 1.064 98.326 1.355
201403 1.190 99.695 1.495
201406 1.122 100.560 1.397
201409 1.126 100.428 1.404
201412 1.145 99.070 1.447
201503 1.226 99.621 1.541
201506 1.145 100.684 1.424
201509 1.119 100.392 1.396
201512 1.114 99.792 1.398
201603 1.208 100.470 1.506
201606 1.193 101.688 1.469
201609 1.108 101.861 1.362
201612 1.100 101.863 1.352
201703 1.271 102.862 1.547
201706 1.177 103.349 1.426
201709 1.166 104.136 1.402
201712 1.226 104.011 1.476
201803 1.321 105.290 1.571
201806 1.210 106.317 1.425
201809 1.238 106.507 1.456
201812 1.200 105.998 1.418
201903 1.170 107.251 1.366
201906 1.129 108.070 1.308
201909 1.186 108.329 1.371
201912 1.104 108.420 1.275
202003 1.333 108.902 1.533
202006 1.960 108.767 2.257
202009 1.472 109.815 1.679
202012 2.122 109.897 2.418
202103 1.932 111.754 2.165
202106 1.440 114.631 1.573
202109 1.731 115.734 1.873
202112 2.006 117.630 2.136
202203 2.513 121.301 2.594
202206 1.524 125.017 1.527
202209 1.466 125.227 1.466

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Meridian Bioscience  (NAS:VIVO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Meridian Bioscience's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=33.97/6.26
=5.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Meridian Bioscience Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (Meridian Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Executives
Julie Diana Smith officer: Sr VP, Controller, PAO 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny director, officer: Chief Executive Officer 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller officer: EVP & CFO ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare officer: Interim CFO & Chief Acctg Off 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii director 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna officer: Executive VP-Diagnostics 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams director C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini officer: Exec VP, Operations & IS 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen officer: EVP, Bus. Development/Strategy 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien officer: EVP, Life Science 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244